176 related articles for article (PubMed ID: 15026360)
21. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
22. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
23. Natural killer group 2D and CD28 receptors differentially activate mammalian/mechanistic target of rapamycin to alter murine effector CD8+ T-cell differentiation.
McQueen B; Trace K; Whitman E; Bedsworth T; Barber A
Immunology; 2016 Mar; 147(3):305-20. PubMed ID: 26661515
[TBL] [Abstract][Full Text] [Related]
24. NKG2D stimulation of CD8
Kavazović I; Lenartić M; Jelenčić V; Jurković S; Lemmermann NAW; Jonjić S; Polić B; Wensveen FM
Eur J Immunol; 2017 Jul; 47(7):1123-1135. PubMed ID: 28378389
[TBL] [Abstract][Full Text] [Related]
25. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
[TBL] [Abstract][Full Text] [Related]
26. NKG2D receptor signaling enhances cytolytic activity by virus-specific CD8+ T cells: evidence for a protective role in virus-induced encephalitis.
Walsh KB; Lanier LL; Lane TE
J Virol; 2008 Mar; 82(6):3031-44. PubMed ID: 18160433
[TBL] [Abstract][Full Text] [Related]
27. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Barber A; Zhang T; DeMars LR; Conejo-Garcia J; Roby KF; Sentman CL
Cancer Res; 2007 May; 67(10):5003-8. PubMed ID: 17510432
[TBL] [Abstract][Full Text] [Related]
28. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer.
Giebel S; Boratyn-Nowicka A; Karabon L; Jedynak A; Pamula-Pilat J; Tecza K; Kula D; Kowal M; Frydecka I; Grzybowska E
Hum Immunol; 2014 Jun; 75(6):508-13. PubMed ID: 24755350
[TBL] [Abstract][Full Text] [Related]
29. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
30. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells.
Karimi M; Cao TM; Baker JA; Verneris MR; Soares L; Negrin RS
J Immunol; 2005 Dec; 175(12):7819-28. PubMed ID: 16339517
[TBL] [Abstract][Full Text] [Related]
31. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors.
Le Maux Chansac B; Moretta A; Vergnon I; Opolon P; Lécluse Y; Grunenwald D; Kubin M; Soria JC; Chouaib S; Mami-Chouaib F
J Immunol; 2005 Nov; 175(9):5790-8. PubMed ID: 16237071
[TBL] [Abstract][Full Text] [Related]
32. NKG2D: A versatile player in the immune system.
Jelenčić V; Lenartić M; Wensveen FM; Polić B
Immunol Lett; 2017 Sep; 189():48-53. PubMed ID: 28414183
[TBL] [Abstract][Full Text] [Related]
33. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.
Zhou H; Luo Y; Lo JF; Kaplan CD; Mizutani M; Mizutani N; Lee JD; Primus FJ; Becker JC; Xiang R; Reisfeld RA
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10846-51. PubMed ID: 16040807
[TBL] [Abstract][Full Text] [Related]
34. 4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells.
Kim YJ; Han MK; Broxmeyer HE
Blood; 2008 Feb; 111(3):1378-86. PubMed ID: 18024793
[TBL] [Abstract][Full Text] [Related]
35. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.
Barber A; Rynda A; Sentman CL
J Immunol; 2009 Dec; 183(11):6939-47. PubMed ID: 19915047
[TBL] [Abstract][Full Text] [Related]
36. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
[TBL] [Abstract][Full Text] [Related]
37. NKG2D is a costimulatory receptor for human naive CD8+ T cells.
Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F
J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668
[TBL] [Abstract][Full Text] [Related]
38. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment.
Roberts AI; Lee L; Schwarz E; Groh V; Spies T; Ebert EC; Jabri B
J Immunol; 2001 Nov; 167(10):5527-30. PubMed ID: 11698420
[TBL] [Abstract][Full Text] [Related]
39. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells.
Burgess SJ; Marusina AI; Pathmanathan I; Borrego F; Coligan JE
J Immunol; 2006 Feb; 176(3):1490-7. PubMed ID: 16424177
[TBL] [Abstract][Full Text] [Related]
40. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
